Lipid lowering therapy in primary prevention in women has been proven to lower cardiovascular events. (quality of evidence I, Grade A recommendation) 
Women at high risk for IHD (diabetics, vascular disease elsewhere) should be treated with pharmacotherapy as per guidelines (consensus, quality of evidence II, Grade A recommendation). 
The 2003 update of the Canadian recommendations for the management of dyslipidemia and the prevention of cardiovascular disease is available throught the CMAJ  and in greater depth at this link.
1. Amberson, B.L., (2000) Risk Factors and Primary Prevention of Ischemic Heart Disease in Women. Canadian Cardiovascular Society Consensus Conference: Women and Ischemic Heart Disease, October 2000: 4/1-4/25.
10. Mosca L, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. AHA/ACC 2004 Scientific Statement. Circulation 2004;109:672-693.
12. Genest J, Frohlich J, Fodor G and McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003; 169 (9):921
accessed March 27, 2006
All references for this section